Catarina Gomes is a Junior Researcher at the Instituto de Investigação e Inovação (I3S), Porto, Portugal. Catarina holds a PhD in Biomedicine (2013) from the Faculty of Medicine University of Porto. Her PhD research was carried at Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), under the supervision of Dr. Celso A Reis, with an international stay at the Center of Biochemistry, Cologne, Germany. Her PhD research focused on the identification of novel cancer serological biomarkers and unravelling molecular signaling pathways in cancer based on aberrant glycan expression. It resulted in 2 first author publications (J Proteome Res. 2013 IF 5; PLosOne 2013 IF 3.5) and 2 provisional patents. In 2014, Catarina was awarded with a competitive FCT PostDoc fellow to pursuit her works, and in 2016 she joined the Copenhagen Center for Glycomics (CCG, Denmark) led by Professor Henrik Clausen. At CCG, Catarina fully integrated a team that both developed a comprehensive library of gRNAs that target most enzymes involved in the synthesis of glycoconjugates (Glycobiology 2018 IF 4.3, Editor’s choice), that are commercially available at Addgene, and established a cell-based method to study the role of glycosaminoglycans in several diseases (Nature Methods 2018 IF 28.55). During her researcher career, Catarina enroll in relevant national and international courses such as Advanced Molecular Technology and Instrumentation for Proteome Analyses (Uppsala, Sweden, 2015), summer schools of Advanced Science on Mass Spectrometry-based Proteomics (Sao Paulo, Brazil, 2017) and course in laboratory animal science Felasa C (Porto, Portugal, 2018). Catarina has been participating in several research projects financed both by national and international institutions. Also, Catarina has been participating in juries of MSc and PhD academic degrees, acting as ah-hoc reviewer for international peer-reviewed journals and expert evaluator of international research programs (e.g. Dioscuri Programme from Max Planck Society). Since 2018, Catarina has been focused in establishing her new research line at i3S on the development of new strategies for cancer drug discovery based on cancer-associated alterations of glycosylation. For that, she has been successful in secure financial support, 2018 FCT funded project (225.417€, PTDC/MED-QUI/29780/2017) and 2021 FCT funded project (249.810€, PTDC/MED-QUI/2335/2021) that permitted the establishment of a motivated research team, currently composed by a hired PostDoc, 2 PhD students (1 as supervisor and 1 as co-supervisor), 1 MSc student and 1 BSc student. Catarina future ambition is to perform investigation with potential to translate into clinically meaningful data.